LeMaitre Vascular's stock dropped 31% after missing Q2 2026 expectations due to currency issues, export blockages, and tissue shortages, but underlying demand remains strong with 10% organic sales growth and record-high margins. The company's fastest-growing product, Artegraft, now accounts for 21% of sales and drives margin expansion and international growth. Despite the valuation reset to 29 times forward earnings, the company's 11% organic growth guidance, solid balance sheet, and expanding biologics portfolio make it a compelling buy. The price target has been adjusted to $95-$100 for year-end 2027.
TPG RE Finance Trust (TRTX) is rated Sell due to its inability to cover dividends with distributable earnings, reporting $0.23 per share against a $0.24 dividend in Q2. Despite higher loan balances, net interest income dropped 5.9% year-over-year, pr...
Leidos and investment firm Altaris have completed their joint venture to create a US-based company under the Analogic brand, combining security screening technologies for airports, borders, and critical infrastructure worldwide. Leidos retains a sign...
MicroStrategy, now rebranded as Strategy, purchased only 334 Bitcoin last week for $28.7 million, a much smaller amount compared to previous weeks. Instead, it spent $176.3 million buying back its preferred stock, which pays a 12% dividend, signaling...
Once Upon a Farm has expanded its product line with new organic Electrolyte Blends designed to support hydration and electrolyte balance in active children. These pouches use real food ingredients like fruits, veggies, coconut water, and sea salt, of...
EPAM Systems has introduced a new AI service designed to support next-generation frontier AI models in handling complex enterprise workflows more reliably. This offering leverages EPAM's extensive experience and partnerships with leading AI labs like...
